{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T18:13:43Z","timestamp":1755800023874,"version":"3.44.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe the efficacy and safety of tofacitinib for pediatric Still's disease, also referred to as systemic-onset juvenile idiopathic arthritis (sJIA). Traditional non-biological drugs and drugs targeting the interleukin-1 and interleukin-6 pathways benefit some patients, but others show inadequate responses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed ten patients with pediatric Still's disease who were treated with tofacitinib and had at least one follow-up visit. Data on patient history, laboratory findings, and treatments were collected at disease onset, at the initiation of tofacitinib, and during follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Tofacitinib led to complete remission in six patients, partial remission in three patients, and loss of efficacy in one patient. Among the nine patients with remission, two discontinued corticosteroids entirely and seven used lower dosages of corticosteroids; these patients also used fewer concurrent medications (1 or 2) after tofacitinib initiation. The one patient who experienced loss of efficacy continued to require a higher dosage of corticosteroids and received five different additional medications. The other nine patients received tocilizumab and had a decreased frequency of these injections after tofacitinib initiation. Tofacitinib was well-tolerated, with only one reported instance of an upper respiratory tract infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Tofacitinib appears to be an effective adjunct therapy for management of pediatric Still's disease, particularly for patients with unstable clinical conditions and adverse reactions to corticosteroids.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1650675","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:34:45Z","timestamp":1755668085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tofacitinib as an adjuvant treatment for pediatric Still's disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Ling","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengguang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.pcl.2018.04.005","article-title":"Systemic juvenile idiopathic arthritis","volume":"65","author":"Lee","year":"2018","journal-title":"Pediatr Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1080\/07853890.2022.2095431","article-title":"Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives","volume":"54","author":"Ambler","year":"2022","journal-title":"Ann Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/acr.23004","article-title":"Tofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient-reported outcomes from a phase III randomized controlled trial","volume":"69","author":"Strand","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13075-018-1539-6","article-title":"Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study","volume":"20","author":"Machado","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/s0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"key":"B6","first-page":"318","article-title":"The mechanism of action of tofacitinib\u2014an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40272-023-00594-7","article-title":"Scope of JAK inhibitors in children: recent evidence and way forward","volume":"25","author":"Bagri","year":"2023","journal-title":"Paediatr Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/1744666x.2022.2047022","article-title":"Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update","volume":"18","author":"Chuprin","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B9","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1093\/rheumatology\/keh710","article-title":"Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?","volume":"44","author":"Ramanan","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1442-200x.1997.tb03593.x","article-title":"Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of a nationwide retrospective survey in Japan","volume":"39","author":"Fujikawa","year":"1997","journal-title":"Acta Paediatr Jpn"},{"key":"B13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12325-013-0047-y","article-title":"Tofacitinib for treatment of rheumatoid arthritis","volume":"30","author":"Rakieh","year":"2013","journal-title":"Adv Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10165-012-0799-2","article-title":"JAK Inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical","volume":"23","author":"Tanaka","year":"2013","journal-title":"Mod Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1177\/1060028013512790","article-title":"Tofacitinib: the first Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis","volume":"47","author":"Vyas","year":"2013","journal-title":"Ann Pharmacother"},{"key":"B16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/1744666x.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/01.NAJ.0000559803.24361.5e","article-title":"Tofacitinib trial prompts FDA review of adverse effects","volume":"119","author":"Aschenbrenner","year":"2019","journal-title":"Am J Nurs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e20182845","DOI":"10.1542\/peds.2018-2845","article-title":"Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis","volume":"143","author":"Huang","year":"2019","journal-title":"Pediatrics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40744-022-00496-z","article-title":"Sequential tocilizumab and tofacitinib treatment for systemic juvenile idiopathic arthritis: a case report","volume":"10","author":"Zhang","year":"2023","journal-title":"Rheumatol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/rheumatology\/keac440","article-title":"JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis","volume":"62","author":"Gillard","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1134312","DOI":"10.3389\/fped.2023.1134312","article-title":"JAK inhibitors in systemic juvenile idiopathic arthritis","volume":"11","author":"He","year":"2023","journal-title":"Front Pediatr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s10067-025-07465-1","article-title":"Tofacitinib as a possible treatment in macrophage activation syndrome: a pilot single-center study in China","volume":"44","author":"Xie","year":"2025","journal-title":"Clin Rheumatol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1650675\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:34:46Z","timestamp":1755668086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1650675\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":24,"alternative-id":["10.3389\/fped.2025.1650675"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1650675","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"article-number":"1650675"}}